Database→Kisspeptin

Tier 2Sexual HealthHormonalMetabolicPREMIUM

Kisspeptin

Kisspeptin (KISS1 Gene Product) · KP-54 / KP-10 / Metastin · Master GnRH Regulator

Not FDA-approved or EMA-approved for any therapeutic indication as of March 2026. No commercial product exists. The Imperial College London research group (Dhillo, Comninos, Abbara), funded by NIHR and the Medical Research Council, has conducted the majority of human clinical trials. 29 interventional clinical trials documented in clinical trial databases. MVT-602 (TAK-448), a synthetic KISS1R agonist analog, has been studied in Myovant Sciences / Takeda-sponsored trials. Not on WADA prohibited list.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Kisspeptin is the endogenous master regulator of the human reproductive axis -- the only peptide whose complete absence causes total reproductive failure in humans. Discovered via KISS1R loss-of-function mutations causing congenital hypogonadotropic hypogonadism, it has 29 completed clinical trials and the most genetically validated mechanism of any compound in this research series. Phase 2 IVF trigger RCTs (n=60 high-OHSS-risk women) achieved 95% oocyte maturation and 45% live birth rate with zero OHSS at any dose. A 2025 eBioMedicine paper established intranasal delivery as a viable non-invasive route, potentially transforming all kisspeptin applications from hospital IV infusion to patient self-administration.

🔒

Full Profile: Premium Members Only

The complete Kisspeptin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use